Tango Therapeutics, Up 39% This Year, Surges Again On Another Cancer Pact

Impact · against what's priced in

Tango Therapeutics and Erasca are likely to see positive price movement following the announcement of a codevelopment agreement to combine vopimetostat and ERAS-0015. The partnership expands the therapeutic potential and pipeline validation for both small-cap biotech firms.

TNGX+0.60

No priced-in read yet

In context

The agreement to codevelop a cancer treatment combining vopimetostat with Erasca's ERAS-0015 provides a new strategic catalyst for the company's pipeline.

Read from the article alone

• biotech▲18%
• healthcare
• ERAS
• TNGX
• cancer treatment
• drug development
• licensing
• partnership

Top 1 mover · tap to explore